JP2023525100A - Craf阻害剤を含む治療的組み合わせ - Google Patents

Craf阻害剤を含む治療的組み合わせ Download PDF

Info

Publication number
JP2023525100A
JP2023525100A JP2022568601A JP2022568601A JP2023525100A JP 2023525100 A JP2023525100 A JP 2023525100A JP 2022568601 A JP2022568601 A JP 2022568601A JP 2022568601 A JP2022568601 A JP 2022568601A JP 2023525100 A JP2023525100 A JP 2023525100A
Authority
JP
Japan
Prior art keywords
melanoma
compound
pharmaceutically acceptable
acceptable salt
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2022568601A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023525100A5 (cg-RX-API-DMAC7.html
Inventor
カポニグロ,ジオルダノ
クック,ヴェセリナ
マーティン スタンベルガー,ウーツ
スチュアート,ダリン
Original Assignee
ノバルティス アーゲー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ノバルティス アーゲー filed Critical ノバルティス アーゲー
Publication of JP2023525100A publication Critical patent/JP2023525100A/ja
Publication of JP2023525100A5 publication Critical patent/JP2023525100A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965—Non-condensed pyrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
JP2022568601A 2020-05-12 2021-05-11 Craf阻害剤を含む治療的組み合わせ Pending JP2023525100A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063023470P 2020-05-12 2020-05-12
US63/023,470 2020-05-12
PCT/IB2021/054013 WO2021229439A1 (en) 2020-05-12 2021-05-11 Therapeutic combinations comprising a craf inhibitor

Publications (2)

Publication Number Publication Date
JP2023525100A true JP2023525100A (ja) 2023-06-14
JP2023525100A5 JP2023525100A5 (cg-RX-API-DMAC7.html) 2024-05-21

Family

ID=75954158

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022568601A Pending JP2023525100A (ja) 2020-05-12 2021-05-11 Craf阻害剤を含む治療的組み合わせ

Country Status (6)

Country Link
US (1) US20240000789A1 (cg-RX-API-DMAC7.html)
EP (1) EP4149472A1 (cg-RX-API-DMAC7.html)
JP (1) JP2023525100A (cg-RX-API-DMAC7.html)
CN (1) CN115551509A (cg-RX-API-DMAC7.html)
TW (1) TW202207942A (cg-RX-API-DMAC7.html)
WO (1) WO2021229439A1 (cg-RX-API-DMAC7.html)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109715163B (zh) 2016-09-19 2022-11-22 诺华股份有限公司 包含raf抑制剂和erk抑制剂的治疗组合
WO2018203219A1 (en) 2017-05-02 2018-11-08 Novartis Ag Combination therapy
EP4563150A3 (en) 2019-05-13 2025-07-23 Novartis AG New crystalline forms of n-(3-(2-(2-hydroxyethoxy)-6-morpholinopyridin-4-yl)-4-methvlphenyl)-2(trifluoromethyl) isonicotinamide as raf inhibitors for the treatment of cancer
TW202440128A (zh) * 2023-01-06 2024-10-16 美商艾瑞斯卡公司 Raf抑制劑及erk1/2及/或shp2抑制劑組合療法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018051306A1 (en) * 2016-09-19 2018-03-22 Novartis Ag Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
WO2018203219A1 (en) * 2017-05-02 2018-11-08 Novartis Ag Combination therapy

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100883289B1 (ko) 2004-06-11 2009-02-11 니뽄 다바코 산교 가부시키가이샤 암 치료용5-아미노-2,4,7-트리옥소-3,4,7,8-테트라히드로-2h-피리도[2,3-d]피리미딘 유도체 및 관련 화합물
GB0719771D0 (en) * 2007-10-10 2007-11-21 Therapeutics Ltd E Dexanabinol in combination with inhibitors of BRAF or MEK for the treatment of melanoma
AU2009284098B2 (en) 2008-08-22 2012-03-29 Astex Therapeutics Ltd. Pyrrolopyrimidine compounds as CDK inhibitors
AR083797A1 (es) 2010-11-10 2013-03-20 Novartis Ag Succinato de dimetil-amida del acido 7-ciclopentil-2-(5-piperazin-1-il-piridin-2-il-amino)-7h-pirrolo-[2,3-d]pirimidin-6-carboxilico, proceso para prepararla, intermediarios de dicha sintesis y proceso de preparacion de los mismos
AR091876A1 (es) * 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
DK2884979T3 (da) * 2012-08-17 2019-09-02 Hoffmann La Roche Kombinationsbehandlinger mod melanom omfattende indgivelse af cobimetinib og vemurafenib
US9242969B2 (en) 2013-03-14 2016-01-26 Novartis Ag Biaryl amide compounds as kinase inhibitors
TWI839690B (zh) * 2013-07-12 2024-04-21 印度商皮拉馬爾企業有限公司 治療黑色素瘤的藥物組合的用途
DK3063143T3 (en) 2013-11-01 2018-08-20 Novartis Ag Amino heteroaryl benzamides as kinase inhibitors
CA2991805A1 (en) * 2015-07-10 2017-01-19 Genmab A/S Axl-specific antibody-drug conjugates for cancer treatment
WO2017037587A1 (en) * 2015-08-28 2017-03-09 Novartis Ag Combination of ribociclib and dabrafenib for treating or preventing cancer
TW202023556A (zh) * 2018-08-27 2020-07-01 美商庫拉腫瘤技術股份有限公司 以mapk路徑抑制劑治療腺癌
CA3123510A1 (en) * 2018-12-20 2020-06-25 Novartis Ag Combination therapy with a raf inhibitor and a cdk4/6 inhibitor for use in the treatment of cancer
TW202140029A (zh) * 2020-02-18 2021-11-01 瑞士商諾華公司 用於治療braf突變型nsclc的包含raf抑制劑之治療組合

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018051306A1 (en) * 2016-09-19 2018-03-22 Novartis Ag Therapeutic combinations comprising a raf inhibitor and a erk inhibitor
WO2018203219A1 (en) * 2017-05-02 2018-11-08 Novartis Ag Combination therapy

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
"Record History: NCT02974725, A Phase Ib Study of LXH254-centric Combinations in NSCLC or Melanoma", CLINICALTRIALS.GOV ARCHIVE [ONLINE], JPN6025024979, 17 January 2019 (2019-01-17), pages 2025 - 06, ISSN: 0005758746 *

Also Published As

Publication number Publication date
US20240000789A1 (en) 2024-01-04
TW202207942A (zh) 2022-03-01
EP4149472A1 (en) 2023-03-22
WO2021229439A1 (en) 2021-11-18
CN115551509A (zh) 2022-12-30

Similar Documents

Publication Publication Date Title
JP7520189B2 (ja) 組み合わせ療法
JP7114575B2 (ja) Raf阻害剤及びerk阻害剤を含む治療用組合せ
US20240000789A1 (en) Therapeutic combinations comprising a craf inhibitor
KR20180041677A (ko) Mdm2 억제제 및 그의 조합물
WO2014203152A1 (en) Pharmaceutical combinations
JP2022514056A (ja) 癌の治療に使用するためのRaf阻害剤及びCDK4/6阻害剤による組み合わせ療法
US20240173293A1 (en) Treatment of Breast Cancer with Amcenestrant and Palbociclib
US20230226030A1 (en) Therapeutic combinations comprising a raf inhibitor for use in treating braf mutant nsclc
KR20230165795A (ko) 벨바라페닙 및 코비메티닙 또는 벨바라페닙, 코비메티닙 및 아테졸리주맙을 이용한 병용 요법
AU2022320615B2 (en) 1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea (gedatolisib) and its combinations for use in the treatment of cancer
EP4203963B1 (en) Combination therapy of naporafenib and trametinib for use in the treatment of sarcoma
JP7709959B2 (ja) 連続的な治療設定における免疫チェックポイント阻害剤に対する患者の応答を高めるためのfgfr遺伝子改変癌におけるfgfr阻害剤の使用
EP4504202B1 (en) Combination therapies comprising gdc-6036 and gdc-0077 for the treatment of cancer
HK40086978A (en) Therapeutic combinations comprising a craf inhibitor
KR20150003786A (ko) Pi3k 저해제 및 mek 저해제를 이용한 암 치료 방법
JP2022547311A (ja) 骨髄線維症の治療のためのmdm2阻害剤の使用
TW202404599A (zh) 使用經取代之嘧啶-4(3h)-酮及納武單抗(nivolumab)之組合療法
TW202508598A (zh) 癌症療法

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240510

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240510

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20241218

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20250221

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250623

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250922

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20251222

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260417